Vicagrel Drug Asset Due Diligence Report 2026

This Vicagrel Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

NDA/BLA

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Vicagrel can convert its Small molecule drug profile and P2Y12 receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Vicagrel (query alias: vicagrel)
Modality / target	Small molecule drug; P2Y12 receptor; P2Y12 receptor antagonists
Highest global status	NDA/BLA
Originator	Jiangsu Vcare PharmaTech Co., Ltd.
Active developers	Jiangsu Vcare PharmaTech Co., Ltd., China Pharmaceutical University, Yiling Pharmaceutical Ltd.

The MCP disease footprint includes Coronary Artery Disease, Ischemic stroke, Peripheral Arterial Disease. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06577519	Phase 3	Recruiting	1000	The incidence of MACE
CTR20244838	Phase 1	已完成	64	Not disclosed
NCT07067775	Phase 1	Completed	18	Area Under the Curve From Time Zero to Last Quantifiable Concentration(AUC）

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Evidence gap

The Clinical Trials MCP returned no matched public result record. This is a gating diligence gap, not evidence of failure.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Vicagrel addresses Coronary Artery Disease, Ischemic stroke, Peripheral Arterial Disease. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2026-06-09	Everest Medicines Enters into Exclusive Asia-Pacific Licensing Agreement with Vcare PharmaTech for Sumecigrel	NDA/BLA	US$2.9M upfront
2012-03-10	江苏威凯尔医药科技有限公司与中国药科大学通过产学研合作维卡格雷（Vicagrel）专家研讨会暨项目启动会在南京召开	Not disclosed	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Method for researching in-vivo fate of Vicagrelor in human plasma and sulfydryl metabolite of Vicagrelor”. The milestone feed surfaced a patent-application signal described as “Detection method and kit for accurately and quantitatively analyzing Vicagrel in human plasma and main metabolites thereof”. The milestone feed surfaced a patent-application signal described as “Pharmaceutical composition containing aspirin and vicagrel”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO